Search

Your search keyword '"Jacobsen, Britta"' showing total 267 results
Start Over Author "Jacobsen, Britta"
267 results on '"Jacobsen, Britta"'

1. Correction: Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

Author

Wiessing, Lucas, Banka-Cullen, Prakashini, Barbaglia, M. Gabriela, Belackova, Vendula, Belbaisi, Saed A. S., Blanken, Peter, Carrieri, Patrizia, Comiskey, Catherine, Dacosta-Sánchez, Daniel, Dom, Geert, Fabricius, Venus, Faria, Hugo, Ignjatova, Liljana, Inić, Nemanja, Jacobsen, Britta, Javakhishvili, Jana D., Kamendy, Zuzana, Kapitány-Fövény, Máté, Kiss, Anna, Kyprianou, Evi, Marchand, Kirsten, Millar, Tim, Mravcik, Viktor, Mustafa, Naser J. Y., Nordt, Carlos, Partanen, Markus, Pedersen, Mads Uffe, Putkonen, Hanna, Razmadze, Mariam, Roux, Perrine, Schulte, Bernd, Seabra, Paulo, Sordo, Luis, Strada, Lisa, Subata, Emilis, Thoma, Esmeralda, Torrens, Marta, Walley, Alexander Y., and Yiasemi, Ioanna

Published
2024
Full Text
View/download PDF

2. Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

Author

Wiessing, Lucas, Banka-Cullen, Prakashini, Barbaglia, M. Gabriela, Belackova, Vendula, Belbaisi, Saed A. S., Blanken, Peter, Carrieri, Patrizia, Comiskey, Catherine, Dacosta-Sánchez, Daniel, Dom, Geert, Fabricius, Venus, Faria, Hugo, Ignjatova, Liljana, Inić, Nemanja, Jacobsen, Britta, Javakhishvili, Jana D., Kamendy, Zuzana, Kapitány-Fövény, Máté, Kiss, Anna, Kyprianou, Evi, Marchand, Kirsten, Millar, Tim, Mravcik, Viktor, Mustafa, Naser J. Y., Nordt, Carlos, Partanen, Markus, Pedersen, Mads Uffe, Putkonen, Hanna, Razmadze, Mariam, Roux, Perrine, Schulte, Bernd, Seabra, Paulo, Sordo, Luis, Strada, Lisa, Subata, Emilis, Thoma, Esmeralda, Torrens, Marta, Walley, Alexander Y., and Yiasemi, Ioanna

Published
2023
Full Text
View/download PDF

5. Alcohol‐Specific Inpatient Diagnoses in Germany: A Retrospective Cross‐Sectional Analysis of Primary and Secondary Diagnoses from 2012 to 2021.

Author

Manthey, Jakob, Jacobsen, Britta, Kilian, Carolin, Kraus, Ludwig, Reimer, Jens, Schäfer, Ingo, and Schulte, Bernd

Subjects
*CROSS-sectional method, *CARDIOVASCULAR diseases, *RESEARCH funding, *SEX distribution, *DISCHARGE planning, *AGE distribution, *RETROSPECTIVE studies, *HOSPITALS, *ALCOHOL-induced disorders, *NOSOLOGY, *DISEASE complications
Abstract

Aims: Our study aimed to a) describe the distribution of hospital discharges with primary and secondary alcohol‐specific diagnoses by sex and age group, and b) describe how the number of hospital discharges with primary and secondary alcohol‐specific diagnoses have changed across different diagnostic groups (categorized by primary International Classification of Diseases, 10th Revision [ICD‐10] diagnosis) over time. Design: Retrospective cross‐sectional analysis. Setting: German hospital settings between 2012 and 2021. Participants: All persons aged 15–69 admitted to hospitals as registered in a nationwide data set. Measurements We counted a) the number of all hospital discharges and b) the number of hospital discharges with at least one alcohol‐specific secondary diagnosis (secondary alcohol‐specific diagnosis) by year, sex, age group, and diagnostic group. One diagnostic group included all primary alcohol‐specific diagnoses, while 13 additional groups aligned with ICD‐10 chapters (e.g., neoplasms). Alcohol‐involvement was defined as either a primary or secondary alcohol‐specific diagnosis. Findings Of 95 417 204 recorded hospital discharges between 2012 and 2021, 3 828 917 discharges (4.0%; 2 913 903 men (6.4%); 915 014 women (1.8%)) involved either a primary or at least one secondary diagnosis related to alcohol. Of all alcohol‐involved hospital discharges, 56.8% (1 654 736 discharges) had no primary but only a secondary alcohol‐specific diagnosis. Secondary alcohol‐specific diagnoses were particularly prevalent in hospital discharges due to injuries. With rising age, alcohol‐involvement in hospital discharges due to digestive or cardiovascular diseases increased. Between 2012 and 2021, the rate of alcohol‐involved hospital discharges has decreased more in younger as compared with older adults (average change between 2012 and 2021: 15–24: −55%; 25–34: −41%; 35–44: −23%; 45–54: −31%; 55–64: −21%; 65–69: −8%). Conclusions: The number of alcohol‐involved hospital discharges in Germany from 2012 to 2021 more than doubles (from 1 654 736 to 3 828 917) when including secondary alcohol‐specific diagnoses. More pronounced declines among younger adults may be attributed to unequal changes in alcohol consumption patterns across the population and to the hazardous effects of long‐term alcohol use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Riluzole suppresses growth and enhances response to endocrine therapy in ER + breast cancer

Author

Olukoya, Ayodeji O, primary, Stires, Hillary, additional, Bahnassy, Shaymaa, additional, Persaud, Sonali, additional, Guerra, Yanira, additional, Ranjit, Suman, additional, Ma, Shihong, additional, Cruz, M Idalia, additional, Benitez, Carlos, additional, Rozeboom, Aaron M, additional, Ceuleers, Hannah, additional, Berry, Deborah L, additional, Jacobsen, Britta M, additional, Raj, Ganesh V, additional, and Riggins, Rebecca B, additional

Published
2023
Full Text
View/download PDF

14. Data from Cooperative Dynamics of AR and ER Activity in Breast Cancer

Author

D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Babbs, Beatrice, primary, Spoelstra, Nicole S., primary, Carson Butterfield, Kiel T., primary, Torkko, Kathleen C., primary, Phan, Vernon T., primary, Barton, Valerie N., primary, Rogers, Thomas J., primary, Sartorius, Carol A., primary, Elias, Anthony, primary, Gertz, Jason, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

15. Supplemental Figure Legends from Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo

Author

Barton, Valerie N., primary, D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Lind, Hanne T., primary, Spoelstra, Nicole S., primary, Babbs, Beatrice L., primary, Heinz, Richard E., primary, Elias, Anthony, primary, Jedlicka, Paul, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Methods from Cooperative Dynamics of AR and ER Activity in Breast Cancer

Author

D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Babbs, Beatrice, primary, Spoelstra, Nicole S., primary, Carson Butterfield, Kiel T., primary, Torkko, Kathleen C., primary, Phan, Vernon T., primary, Barton, Valerie N., primary, Rogers, Thomas J., primary, Sartorius, Carol A., primary, Elias, Anthony, primary, Gertz, Jason, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure Legends from Cooperative Dynamics of AR and ER Activity in Breast Cancer

Author

D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Babbs, Beatrice, primary, Spoelstra, Nicole S., primary, Carson Butterfield, Kiel T., primary, Torkko, Kathleen C., primary, Phan, Vernon T., primary, Barton, Valerie N., primary, Rogers, Thomas J., primary, Sartorius, Carol A., primary, Elias, Anthony, primary, Gertz, Jason, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Tables 1-3 from Cooperative Dynamics of AR and ER Activity in Breast Cancer

Author

D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Babbs, Beatrice, primary, Spoelstra, Nicole S., primary, Carson Butterfield, Kiel T., primary, Torkko, Kathleen C., primary, Phan, Vernon T., primary, Barton, Valerie N., primary, Rogers, Thomas J., primary, Sartorius, Carol A., primary, Elias, Anthony, primary, Gertz, Jason, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

19. Data from Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo

Author

Barton, Valerie N., primary, D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Lind, Hanne T., primary, Spoelstra, Nicole S., primary, Babbs, Beatrice L., primary, Heinz, Richard E., primary, Elias, Anthony, primary, Jedlicka, Paul, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figures S1-S6 from Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo

Author

Barton, Valerie N., primary, D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Lind, Hanne T., primary, Spoelstra, Nicole S., primary, Babbs, Beatrice L., primary, Heinz, Richard E., primary, Elias, Anthony, primary, Jedlicka, Paul, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figures 1-6 from Cooperative Dynamics of AR and ER Activity in Breast Cancer

Author

D'Amato, Nicholas C., primary, Gordon, Michael A., primary, Babbs, Beatrice, primary, Spoelstra, Nicole S., primary, Carson Butterfield, Kiel T., primary, Torkko, Kathleen C., primary, Phan, Vernon T., primary, Barton, Valerie N., primary, Rogers, Thomas J., primary, Sartorius, Carol A., primary, Elias, Anthony, primary, Gertz, Jason, primary, Jacobsen, Britta M., primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data from Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers

Author

Wahdan-Alaswad, Reema S., primary, Edgerton, Susan M., primary, Salem, Hiba, primary, Kim, Hyun Min, primary, Tan, Aik Choon, primary, Finlay-Schultz, Jessica, primary, Wellberg, Elizabeth A., primary, Sartorius, Carol A., primary, Jacobsen, Britta M., primary, Haugen, Bryan R., primary, Liu, Bolin, primary, and Thor, Ann D., primary

Published
2023
Full Text
View/download PDF

24. Data from Loss of E-cadherin Enhances IGF1–IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors

Author

Nagle, Alison M., primary, Levine, Kevin M., primary, Tasdemir, Nilgun, primary, Scott, Julie A., primary, Burlbaugh, Kara, primary, Kehm, Justin, primary, Katz, Tiffany A., primary, Boone, David N., primary, Jacobsen, Britta M., primary, Atkinson, Jennifer M., primary, Oesterreich, Steffi, primary, and Lee, Adrian V., primary

Published
2023
Full Text
View/download PDF

25. Supplemental Table 1 from Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer

Author

Williams, Michelle M., primary, Spoelstra, Nicole S., primary, Arnesen, Spencer, primary, O'Neill, Kathleen I., primary, Christenson, Jessica L., primary, Reese, Jordan, primary, Torkko, Kathleen C., primary, Goodspeed, Andrew, primary, Rosas, Emmanuel, primary, Hanamura, Toru, primary, Sams, Sharon B., primary, Li, Zheqi, primary, Oesterreich, Steffi, primary, Riggins, Rebecca B., primary, Jacobsen, Britta M., primary, Elias, Anthony, primary, Gertz, Jason, primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures / Table from Loss of E-cadherin Enhances IGF1–IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors

Author

Nagle, Alison M., primary, Levine, Kevin M., primary, Tasdemir, Nilgun, primary, Scott, Julie A., primary, Burlbaugh, Kara, primary, Kehm, Justin, primary, Katz, Tiffany A., primary, Boone, David N., primary, Jacobsen, Britta M., primary, Atkinson, Jennifer M., primary, Oesterreich, Steffi, primary, and Lee, Adrian V., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure Legends from Loss of E-cadherin Enhances IGF1–IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors

Author

Nagle, Alison M., primary, Levine, Kevin M., primary, Tasdemir, Nilgun, primary, Scott, Julie A., primary, Burlbaugh, Kara, primary, Kehm, Justin, primary, Katz, Tiffany A., primary, Boone, David N., primary, Jacobsen, Britta M., primary, Atkinson, Jennifer M., primary, Oesterreich, Steffi, primary, and Lee, Adrian V., primary

Published
2023
Full Text
View/download PDF

31. Supplemental Figures S1-S11 from Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer

Author

Williams, Michelle M., primary, Spoelstra, Nicole S., primary, Arnesen, Spencer, primary, O'Neill, Kathleen I., primary, Christenson, Jessica L., primary, Reese, Jordan, primary, Torkko, Kathleen C., primary, Goodspeed, Andrew, primary, Rosas, Emmanuel, primary, Hanamura, Toru, primary, Sams, Sharon B., primary, Li, Zheqi, primary, Oesterreich, Steffi, primary, Riggins, Rebecca B., primary, Jacobsen, Britta M., primary, Elias, Anthony, primary, Gertz, Jason, primary, and Richer, Jennifer K., primary

Published
2023
Full Text
View/download PDF

36. Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer.

Author

Olukoya, Ayodeji O, Stires, Hillary, Bahnassy, Shaymaa, Persaud, Sonali, Guerra, Yanira, Ranjit, Suman, Ma, Shihong, Cruz, M Idalia, Benitez, Carlos, Rozeboom, Aaron M, Ceuleers, Hannah, Berry, Deborah L, Jacobsen, Britta M, Raj, Ganesh V, and Riggins, Rebecca B

Subjects
LOBULAR carcinoma, ESTROGEN, HORMONE therapy, RILUZOLE, CANCER cell growth, BREAST cancer, AMYOTROPHIC lateral sclerosis
Abstract

Background Resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancer remains a significant clinical problem. Riluzole is FDA-approved for the treatment of amyotrophic lateral sclerosis. A benzothiazole-based glutamate release inhibitor with several context-dependent mechanism(s) of action, riluzole has shown antitumor activity in multiple malignancies, including melanoma, glioblastoma, and breast cancer. We previously reported that the acquisition of tamoxifen resistance in a cellular model of invasive lobular breast cancer is accompanied by the upregulation of GRM mRNA expression and growth inhibition by riluzole. Methods We tested the ability of riluzole to reduce cell growth, alone and in combination with endocrine therapy, in a diverse set of ER+ invasive ductal and lobular breast cancer–derived cell lines, primary breast tumor explant cultures, and the estrogen-independent, ESR1 -mutated invasive lobular breast cancer patient-derived xenograft model HCI-013EI. Results Single-agent riluzole suppressed the growth of ER+ invasive ductal and lobular breast cancer cell lines in vitro, inducing a histologic subtype-associated cell cycle arrest (G0-G1 for ductal, G2-M for lobular). Riluzole induced apoptosis and ferroptosis and reduced phosphorylation of multiple prosurvival signaling molecules, including Akt/mTOR, CREB, and Fak/Src family kinases. Riluzole, in combination with either fulvestrant or 4-hydroxytamoxifen, additively suppressed ER+ breast cancer cell growth in vitro. Single-agent riluzole significantly inhibited HCI-013EI patient-derived xenograft growth in vivo, and the combination of riluzole plus fulvestrant significantly reduced proliferation in ex vivo primary breast tumor explant cultures. Conclusion Riluzole may offer therapeutic benefits in diverse ER+ breast cancers, including lobular breast cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Effects of legalizing cannabis

Author

Manthey, Jakob, Hayer, Tobias, Jacobsen, Britta, Kalke, Jens, Klinger, Sinja, Rehm, Jurgen, Rosenkranz, Moritz, Verthein, Uwe, Wirth, Marielle, Armstrong, Michael, Myran, Daniel, Pacula, Rosalie Liccardo, Queirolo, Rosario, and Zobel, Frank

Published
2023
Full Text
View/download PDF

41. Umsetzung von Testung, Diagnostik und Behandlung der Hepatitis C in Einrichtungen der niedrigschwelligen Drogenhilfe in Deutschland – eine Querschnittsbefragung : [Implementation of testing, diagnostic and treatment of hepatitis C in low-threshold drug help facilities in Germany - a cross-sectional survey]

Author

Schulte, Bernd, Jacobsen, Britta, Kuban, Maria, Kraus, Ludwig, Reimer, Jens, Schmidt, Christiane Sybille, Schaeffer, Dirk, Schulte, Bernd, Jacobsen, Britta, Kuban, Maria, Kraus, Ludwig, Reimer, Jens, Schmidt, Christiane Sybille, and Schaeffer, Dirk

Abstract

Background AIDS and drug aid facilities offer a low-threshold access for people with injecting and other forms of drug use and thus play a central role in reducing hepatitis C virus (HCV) infections in this high-risk group. The aim of this study is to describe the provision and barriers of HCV-specific measures in facilities with low-threshold services for drug users in Germany. Method The cross-sectional survey addressed facility structures, availability of HCV-specific measures (prevention, testing, diagnostics, therapy), structural, facility-related and patient-related barriers. The allocation of consumer paraphernalia was used as a criterion for the selection of facilities with low-threshold access for people with injecting and other forms of drug use. The data analysis was carried out descriptively by summarizing and analyzing facilities based on their characteristics. Results Of the 380 facilities contacted, responses from 135 facilities with low-threshold access for people with injecting and other forms of drug use were included in the analysis. Most of the facilities offer information on safer use (98.5%) and HCV-counselling (87.4 %). Around 28% of the facilities have HCV antibody or rapid tests available. 40% and 64.4% of all facilities stated that clients with a positive antibody test result or with a corresponding diagnosis (e.g. chronic HCV infection) can be referred to medical care. Insufficient funding and client-related barriers (e.g. lack of reliability) were mentioned as the main barriers to improving the implementation of HCV-specific measures. Conclusions While general HCV-prevention measures are an integral part of low-threshold services for drug users in Germany, the availability and uptake of HCV testing and HCV care services for people with injecting and other forms of drug use is not sufficient to significantly reduce HCV infections in this high-risk group. In addition to adequate funding, client-centered interventions are needed to improve t, Hintergrund Einrichtungen der Aids- und Drogenhilfe bieten einen niedrigschwelligen Zugang für Menschen mit injizierendem und anderen Drogenkonsumformen und spielen somit eine zentrale Rolle für die Eindämmung von Hepatitis C Virus (HCV)-Infektionen in dieser Hochrisikogruppe. Ziel dieser Studie ist es, die Versorgungsleistungen sowie Barrieren von HCV-spezifischen Maßnahmen in Einrichtungen der Aids- und Drogenhilfe mit niedrigschwelligen Angeboten in Deutschland zu beschreiben. Methode Die Querschnittsbefragung adressierte Einrichtungsstrukturen, Verfügbarkeit von HCV-spezifischen Maßnahmen (Prävention, Testung, Diagnostik, Therapie), strukturelle, einrichtungsbezogene und patient:innenbezogene Barrieren. Die Vergabe von Konsumutensilien wurde als Kriterium für die Auswahl von Einrichtungen mit einem niedrigschwelligen Zugang für Menschen mit injizierendem und anderen Drogenkonsumformen herangezogen. Die Datenanalyse erfolgte deskriptiv, indem Einrichtungen anhand ihrer Merkmale zusammengefasst, beschrieben und analysiert wurden. Ergebnisse Von 380 kontaktierten Einrichtungen gingen Antworten von 135 Einrichtungen mit einer Vergabe von Konsumutensilien in die Auswertung ein. Der Großteil der Einrichtungen bot Informationen zu „Safer Use“ (98,5%) und Beratungen zu HCV (87,4%) an. Etwa 28% der Einrichtungen verfügten über HCV-Antikörper bzw. Schnelltestangebote. 40% bzw. 64,4% aller Einrichtungen gaben an, dass Klient:innen mit einem positiven Antikörpertestergebnis bzw. mit einer entsprechenden Diagnose (z. B. chronische HCV-Infektion) in die medizinische Versorgung weitervermittelt werden können. Als Hauptbarrieren für eine verbesserte Umsetzung von HCV-spezifischen Maßnahmen wurden ungenügende Finanzierung und klient:innenbezogene Barrieren (z. B. mangelnde Zuverlässigkeit) genannt. Schlussfolgerungen Während Maßnahmen zur HCV-Prävention integraler Bestandteil der niedrigschwelligen Drogenhilfe sind, ist die Verfügbarkeit und Inanspruchnahme von HCV-Test- und Ver

Published
2022
Full Text
View/download PDF

50. Additional file 1 of New generation breast cancer cell lines developed from patient-derived xenografts

Author

Finlay-Schultz, Jessica, Jacobsen, Britta M., Riley, Duncan, Paul, Kiran V., Turner, Scott, Ferreira-Gonzalez, Andrea, J. Chuck Harrell, Kabos, Peter, and Sartorius, Carol A.

Abstract

Additional file : Supplemental Figure 1. IHC of PDX from which cell lines were derived. PDX were stained with antibodies to ER, PR, AR, CK5, and CK8/18. Slides were loaded into Aperio digital slide viewer and images captured at 40x magnification with Imagescope (Leica). Supplemental Figure 2. Nuclear-GFP labeled UCD cell lines for proliferation assays. Representative images of UCD cell lines during Incucyte analysis. Individual wells were captured at 6-18 h post plating. Mag bars,300 microns. Supplemental Fig. 3. Growth of UCD cell lines in vivo. One million cells were inoculated billaterally into the #4 mammary fat pads of NSG mice. Animals were supplemented with slow release estrogen pellets and tumors measure weekly. Mean plus SEM are indicated. N=6 tumors UCD12 and UCD47 and N = 3 tumors forUCD65. Supplemental Figure 4. Expressison profiles of UCD cell lines show moderate to strong positive correlation to their PDX tumors of origin. The RNA-seq expression profiles (FPKM) of UCD cell lines and UCD PDX were compared using the r package ggpubr. The r2 correlation and p values were plotted for each cell line and thecorresponding PDX. Supplementary Figure 5. Vimentin expression in ER negative UCD cell lines. UCD46, UCD115, and UCD178 cells were plated on glass slides in regular media. Cells were fixed and stained by immunocytochemistry with an antibody to vimentin with DAPI counterstain. Scale bar, 50 μM.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results